

Vassilis Georgoulas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8243055/vassilis-georgoulas-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

3,228
citations

31
h-index

56
g-index

87
ext. papers

3,564
ext. citations

4.9
avg, IF

4.79
L-index

#	Paper	IF	Citations
80	Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. <i>Cancers</i> , 2021 , 13,	6.6	7
79	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 277-287	3.5	3
78	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. <i>Scientific Reports</i> , 2021 , 11, 2313	4.9	12
77	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1037-1048	3.8	2
76	Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
75	CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 17588359198954	5.4	6
74	MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2019 , 14, 285-293	5	6
73	The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. <i>Breast Cancer Research</i> , 2019 , 21, 86	8.3	12
72	Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment. <i>Lung Cancer</i> , 2019 , 135, 33-39	5.9	10
71	Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20086-e20086	2.2	0
70	Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. <i>Minerva Ginecologica</i> , 2019 , 71, 182-190	1.2	0
69	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758834017750121	5.4	47
68	Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. <i>Scientific Reports</i> , 2018 , 8, 22384	4.9	11
67	Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018 , 24, 1500-1510	12.9	98
66	Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 767-775	3.5	14
65	PD-L1+CD4+ T cells and soluble PD-L1 as prognostic factors to anti-PD-1 immunotherapy in advanced non small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24091-e24091	2.2	
64	Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment. <i>Lung Cancer</i> , 2018 , 124, 270-278	5.9	17

63	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. <i>Lancet Oncology, The</i> , 2017 , 18, 556-557	21.7	18
62	TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). <i>Scientific Reports</i> , 2017 , 7, 45351	4.9	16
61	Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017 , 12, e0181211	3.7	21
60	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 5309-5322	3.3	24
59	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017 , 44, 594-606	3.9	31
58	Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). <i>Cellular Physiology and Biochemistry</i> , 2016 , 40, 411-419	3.9	34
57	Effect of 2nd line pazopanib (PZN) on the number and phenotype of CTCs in patients with small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8562-8562	2.2	
56	Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1505-19	4	8
55	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). <i>European Journal of Cancer</i> , 2015 , 51, 1511-28	7.5	23
54	The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. <i>Cancers</i> , 2015 , 7, 439-49	6.6	2
53	Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 875-84	3.5	8
52	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015 , 17, 113	8.3	21
51	Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7573-7573	2.2	1
50	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0123683	3.7	38
49	The optimum duration of front-line chemotherapy. <i>Lancet Oncology, The</i> , 2014 , 15, 1187-8	21.7	
48	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. <i>Breast Cancer Research</i> , 2014 , 16, 485	8.3	42
47	A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. <i>Journal of Immunology Research</i> , 2014 , 2014, 659294	4.5	80
46	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014 , 14, 651	4.8	75

45	Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11042-11042	2.2	
44	Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell transplantation. <i>Anticancer Research</i> , 2014 , 34, 5111-5	2.3	5
43	Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. <i>Molecular Cancer Research</i> , 2013 , 11, 1248-57	6.6	50
42	A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. <i>Journal of Chemotherapy</i> , 2013 , 25, 49-55	2.3	39
41	Apoptotic circulating tumor cells in early and metastatic breast cancer patients. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1886-95	6.1	77
40	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPOIIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. <i>PLoS ONE</i> , 2013 , 8, e74611	3.7	29
39	BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients outcome. <i>PLoS ONE</i> , 2013 , 8, e84604	3.7	40
38	A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 35-42	3.5	29
37	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 351-6	3.5	7
36	Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. <i>Supportive Care in Cancer</i> , 2012 , 20, 1823-9	3.9	41
35	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2011 , 13, R59	8.3	271
34	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011 , 13, R60	8.3	66
33	Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 2 nd line cetuximab-based therapy of colorectal cancer patients. <i>PLoS ONE</i> , 2011 , 6, e15980	3.7	101
32	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 851-63	4	17
31	Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 361-8	3.5	21
30	A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1239-45	3.5	19
29	Multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 63-8	3.5	12
28	A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 415-22	3.5	1

27	Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 165-73	12.9	17
26	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2363-89	4	18
25	PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 697-704	5.1	28
24	FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 95-104	4.4	35
23	Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. <i>Journal of Neuro-Oncology</i> , 2010 , 97, 291-4	4.8	8
22	A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2010 , 30, 4335-42	2.3	4
21	Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2177-84	2.2	225
20	Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1470-7	4.6	38
19	Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 525-34	4.4	41
18	A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 785-91	3.5	1
17	A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 121-8	3.5	
16	Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009 , 11, R84	8.3	93
15	Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. <i>Lung Cancer</i> , 2008 , 59, 57-63	5.9	36
14	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2008 , 10, R80	8.3	103
13	Docetaxel in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1207-22	3.5	41
12	Paclitaxel and docetaxel in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2603-16	4	83
11	Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2593-600	12.9	197
10	Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. <i>PLoS ONE</i> , 2008 , 3, e3695	3.7	99

9	A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 449-56	3.5	2
8	Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. <i>Molecular Medicine</i> , 2007 , 13, 79-88	6.2	66
7	Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5194-202	2.2	208
6	Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. <i>Oncology</i> , 2006 , 70, 280-4	3.6	22
5	Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3756-62	2.2	245
4	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. <i>Breast Cancer Research</i> , 2006 , 8, R36	8.3	28
3	High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. <i>Lung Cancer</i> , 2004 , 44, 363-8	5.9	53
2	A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer. <i>Anticancer Research</i> , 2004 , 24, 4217-21	2.3	1
1	Docetaxel (taxotere) in the treatment of non-small cell lung cancer. <i>Current Medicinal Chemistry</i> , 2002 , 9, 869-77	4.3	16